At present, there is relatively limited in vivo data relating to this approach, in contrast to the large number of patients who have participated in clinical trials of (noninducible) AAV-based gene therapy, for either PD or for other diseases such as Alzheimer???s or Canavan disease, without any major safety concerns being raised [12, 59, 62, 100, 101].